Antiepileptic drugs /
Saved in:
| Edition: | 5th ed. |
|---|---|
| Imprint: | Philadelphia : Lippincott Williams & Wilkins, c2002. |
| Description: | xv, 968 p. : ill. ; 29 cm. |
| Language: | English |
| Subject: | Epilepsy -- Chemotherapy. Anticonvulsants. Anticonvulsants -- therapeutic use. Anticonvulsants -- pharmacology. Epilepsy -- drug therapy. Anticonvulsants. Epilepsy -- Chemotherapy. |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/4746692 |
| LEADER | 09787pam a22004694a 4500 | ||
|---|---|---|---|
| 001 | 4746692 | ||
| 003 | ICU | ||
| 005 | 20031021183400.0 | ||
| 008 | 020722s2002 paua b 001 0 eng | ||
| 010 | |a 2002030011 | ||
| 020 | |a 0781723213 | ||
| 035 | |a 2002030011 | ||
| 035 | |a (DNLM)101150747 | ||
| 035 | |a (OCoLC)50285309 | ||
| 040 | |a DNLM/DLC |c DLC |d NhCcYBP |d OCoLC |d OrLoB-B | ||
| 042 | |a pcc | ||
| 050 | 0 | 0 | |a RC374.C48 |b A58 2002 |
| 060 | 1 | 0 | |a QV 85 |b A628 2002 |
| 082 | 0 | 0 | |a 616.8/53061 |2 21 |
| 245 | 0 | 0 | |a Antiepileptic drugs / |c editors, René H. Levy ... [et al.]. |
| 250 | |a 5th ed. | ||
| 260 | |a Philadelphia : |b Lippincott Williams & Wilkins, |c c2002. | ||
| 300 | |a xv, 968 p. : |b ill. ; |c 29 cm. | ||
| 336 | |a text |b txt |2 rdacontent |0 http://id.loc.gov/vocabulary/contentTypes/txt | ||
| 337 | |a unmediated |b n |2 rdamedia |0 http://id.loc.gov/vocabulary/mediaTypes/n | ||
| 338 | |a volume |b nc |2 rdacarrier |0 http://id.loc.gov/vocabulary/carriers/nc | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | 0 | |g Sect. I. |t General Principles -- |g 1. |t Principles of Antiepileptic Drug Action / |r Michael A. Rogawski -- |g 2. |t Neurophysiological Effects of Antiepileptic Drugs / |r Carl W. Bazil and Timothy A. Pedley -- |g 3. |t Discovery and Preclinical Development of Antiepileptic Drugs / |r H. Steve White, Jose H. Woodhead and Karen S. Wilcox / |r [et al.] -- |g 4. |t New Antiepileptic Drug Development: Medical Perspective / |r Jacqueline A. French and Marc A. Dichter -- |g 5. |t Clinical Development of Antiepileptic Drugs: Industry Perspective / |r Roger J. Porter -- |g 6. |t The Development of Antiepilepsy Drugs: Regulatory Perspective / |r Russell Katz -- |g 7. |t Antiepileptic Drug Monotherapy in Adults: Selection and Use in New-Onset Epilepsy / |r Richard H. Mattson -- |g 8. |t Combination Therapy and Drug Interactions / |r Emilio Perucca and Rene H. Levy -- |g 9. |t Laboratory Monitoring of Antiepileptic Drugs / |r Svein I. Johannessen and Torbjorn Tomson -- |g 10. |t Safety Monitoring of Antiepileptic Drugs / |r L. James Willmore -- |g 11. |t Use of Antiepileptic Drugs in Children / |r Olivier Dulac -- |g 12. |t Antiepileptic Drug Use in Women / |r Martha J. Morrell -- |g 13. |t Epilepsy in the Elderly / |r Ilo E. Leppik and James C. Cloyd -- |g 14. |t Treatment of Status Epilepticus / |r Brian K. Alldredge -- |g 15. |t Prevention of Epileptogenesis / |r Asla Pitkanen -- |g Sect. II. |t Benzodiazepines -- |g 16. |t Mechanisms of Action / |r Robert L. Macdonald -- |g 17. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Gail D. Anderson and John W. Miller -- |g 18. |t Clinical Efficacy and Use in Epilepsy / |r Dieter Schmidt -- |g 19. |t Adverse Effects / |r Roberto Michelucci and Carlo Alberto Tassinari -- |g Sect. III. |t Carbamazepine -- |g 20. |t Mechanisms of Action / |r Robert L. Macdonald -- |g 21. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Edoardo Spina -- |g 22. |t Interactions with Other Drugs / |r Colleen J. Wurden and Rene H. Levy -- |g 23. |t Clinical Efficacy and Use in Epilepsy / |r Pierre Loiseau -- |g 24. |t Clinical Efficacy and Use in Other Neurological Disorders / |r Ettore Beghi -- |g 25. |t Clinical Efficacy and Use in Psychiatric Disorders / |r Michael R. Trimble -- |g 26. |t Adverse Effects / |r Gregory L. Holmes -- |g Sect. IV. |t Felbamate -- |g 27. |t Felbamate / |r John M. Pellock, James L. Perhach and R. Duane Sofia -- |g Sect. V. |t Gabapentin -- |g 28. |t Mechanisms of Action / |r Charles P. Taylor -- |g 29. |t Chemistry, Biotransformation, Pharmacokinetics, and Interactions / |r Frank J. E. Vajda -- |g 30. |t Clinical Use / |r Anthony G. Marson and David W. Chadwick -- |g 31. |t Clinical Efficacy and Use in Other Neurological Disorders / |r Bernd Schmidt -- |g 32. |t Clinical Efficacy and Use in Psychiatric Disorders / |r John H. Greist -- |g 33. |t Adverse Effects / |r R. Eugene Ramsay and Flavia M. Pryor -- |g Sect. VI. |t Lamotrigine -- |g 34. |t Mechanisms of Action / |r Michael J. Leach, Andrew D. Randall and Alessandro Stefani / |r [et al.] -- |g 35. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Maurice Dickins and Chao Chen -- |g 36. |t Interactions with Other Drugs / |r William R. Garnett -- |g 37. |t Clinical Efficacy and Use in Epilepsy / |r Linda J. Stephen and Martin J. Brodie -- |g 38. |t Efficacy and Use in Nonepileptic Disorders / |r Melvin D. Shelton and Joseph R. Calabrese -- |g 39. |t Adverse Effects / |r Francesco Pisani and Alan Richens -- |g Sect. VII. |t Levetiracetam -- |g 40. |t Mechanisms of Action / |r Doru Georg Margineanu and Henrik Klitgaard -- |g 41. |t Chemistry, Biotransformation, Pharmacokinetics, and Drug Interactions / |r Philip N. Patsalos -- |g 42. |t Clinical Use / |r Ilo E. Leppik -- |g 43. |t Adverse Experiences / |r Victor Biton -- |g Sect. VIII. |t Oxcarbazepine -- |g 44. |t Mechanisms of Action / |r Michael J. McLean -- |g 45. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Meir Bialer -- |g 46. |t Interactions with Other Drugs / |r Fiorenzo Albani, Roberto Riva and Agostino Baruzzi -- |g 47. |t Clinical Efficacy and Use in Epilepsy / |r Steven C. Schachter -- |g 48. |t Clinical Efficacy and Use in Psychiatric Disorders / |r Michael R. Trimble -- |g 49. |t Adverse Effects / |r Gunter Kramer -- |g Sect. IX. |t Phenobarbital and Other Barbiturates -- |g 50. |t Mechanisms of Action / |r Richard W. Olsen -- |g 51. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Gail D. Anderson -- |g 52. |t Interactions with Other Drugs / |r J. Steven Leeder -- |g 53. |t Clinical Efficacy and Use in Epilepsy / |r Michel Baulac -- |g 54. |t Clinical Efficacy and Use in Nonepileptic Disorders / |r Ettore Beghi -- |g 55. |t Adverse Effects / |r Michel Baulac, Joyce A. Cramer and Richard H. Mattson -- |g 56. |t Methylphenobarbital / |r Mervyn J. Eadie and Wayne D. Hooper -- |g Sect. X. |t Phenytoin and Other Hydantoins -- |g 57. |t Mechanisms of Action / |r Robert J. DeLorenzo and David A. Sun -- |g 58. |t Chemistry and Biotransformation / |r Thomas R. Browne and Barbara LeDuc -- |g 59. |t Interactions with Other Drugs / |r Isabelle Ragueneau-Majlessi, Manoj Bajpai and Rene H. Levy -- |g 60. |t Clinical Efficacy and Use in Epilepsy / |r B. Joe Wilder and Joseph Bruni -- |g 61. |t Clinical Efficacy and Use in Other Neurological Disorders / |r Ettore Beghi -- |g 62. |t Clinical Efficacy and Use in Psychiatric Disorders / |r Francesco Monaco and Marco Mula -- |g 63. |t Adverse Effects / |r Joseph Bruni -- |g 64. |t Fosphenytoin / |r Flavia M. Pryor and R. Eugene Ramsay -- |g Sect. XI. |t Primidone -- |g 65. |t Primidone / |r Richard W. Fincham and Dorothy D. Schottelius -- |g Sect. XII. |t Succinimides -- |g 66. |t Mechanisms of Action / |r Katherine D. Holland and James A. Ferrendelli -- |g 67. |t Ethosuximide: Chemistry, Biotransformation, Pharmacokinetics, and Drug Interactions / |r Francesco Pisani, Emilio Perucca and Meir Bialer -- |g 68. |t Clinical Efficacy and Use in Epilepsy / |r Allan L. Sherwin -- |g 69. |t Adverse Effects / |r Tracy A. Glauser -- |g 70. |t Methsuximide / |r Thomas R. Browne -- |g Sect. XIII. |t Tiagabine -- |g 71. |t Mechanisms of Action / |r William J. Giardina -- |g 72. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Kenneth W. Sommerville and Stephen D. Collins -- |g 73. |t Drug Interactions / |r Kenneth W. Sommerville -- |g 74. |t Clinical Efficacy and Use in Epilepsy / |r Reetta Kalviainen -- |g 75. |t Clinical Efficacy and Use in Nonepileptic Disorders / |r Kenneth W. Sommerville -- |g 76. |t Adverse Effects / |r Steven C. Schachter -- |g Sect. XIV. |t Topiramate -- |g 77. |t Mechanisms of Action / |r H. Steve White -- |g 78. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Dennis R. Doose and Anthony J. Streeter -- |g 79. |t Drug Interactions / |r Barry E. Gidal -- |g 80. |t Clinical Efficacy and Use in Epilepsy / |r Michael D. Privitera and Roy E. Twyman -- |g 81. |t Clinical Efficacy and Use in Nonepileptic Disorders / |r Marc Kamin -- |g 82. |t Adverse Effects / |r Rajesh C. Sachdeo and Roopal M. Karia -- |g Sect. XV. |t Valproic Acid -- |g 83. |t Mechanisms of Action / |r Wolfgang Loscher -- |g 84. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Rene H. Levy, Danny D. Shen and Frank S. Abbott / |r [et al.] -- |g 85. |t Drug Interactions / |r Richard D. Scheyer -- |g 86. |t Clinical Efficacy and Use in Epilepsy / |r Blaise F. D. Bourgeois -- |g 87. |t Clinical Efficacy and Use in Other Neurological Disorders / |r Stephen D. Silberstein -- |g 88. |t Clinical Efficacy and Use in Psychiatric Disorders / |r Alan C. Swann -- |g 89. |t Adverse Effects / |r Pierre Genton and Philippe Gelisse -- |g Sect. XVI. |t Vigabatrin -- |g 90. |t Vigabatrin / |r Elinor Ben-Menachem -- |g Sect. XVII. |t Zonisamide -- |g 91. |t Mechanisms of Action / |r Robert L. Macdonald -- |g 92. |t Chemistry, Biotransformation, and Pharmacokinetics / |r Jaymin Shah, Kent Shellenberger and Daniel M. Canafax -- |g 93. |t Drug Interactions / |r Gary G. Mather and Jaymin Shah -- |g 94. |t Clinical Efficacy and Use in Epilepsy / |r Masakazu Seino and Buichi Fujitani -- |g 95. |t Adverse Effects / |r Byung In Lee -- |g Sect. XVIII. |t Drugs in Development -- |g 96. |t Pregabalin / |r Elinor Ben-Menachem and Alan R. Kugler -- |g 97. |t Rufinamide / |r Mary Ann Karolchyk and Dieter Schmidt -- |g 98. |t Drugs in Early Clinical Development / |r Emilio Perucca and Harvey J. Kupferberg. |
| 650 | 0 | |a Epilepsy |x Chemotherapy. |0 http://id.loc.gov/authorities/subjects/sh2008119833 | |
| 650 | 0 | |a Anticonvulsants. |0 http://id.loc.gov/authorities/subjects/sh85005657 | |
| 650 | 1 | 2 | |a Anticonvulsants |x therapeutic use. |
| 650 | 2 | 2 | |a Anticonvulsants |x pharmacology. |
| 650 | 2 | 2 | |a Epilepsy |x drug therapy. |
| 650 | 7 | |a Anticonvulsants. |2 fast |0 http://id.worldcat.org/fast/fst00810472 | |
| 650 | 7 | |a Epilepsy |x Chemotherapy. |2 fast |0 http://id.worldcat.org/fast/fst00914186 | |
| 700 | 1 | |a Levy, René H. |0 http://id.loc.gov/authorities/names/n82251883 |1 http://viaf.org/viaf/51805614 | |
| 901 | |a ToCBNA | ||
| 903 | |a HeVa | ||
| 929 | |a cat | ||
| 999 | f | f | |i c0fb4d81-cdb7-50e1-8804-988ae6c9705f |s 03c1eb11-ba84-5ce8-8dbc-847a7ebffd90 |
| 928 | |t Library of Congress classification |a RC374.C48 A58 2002 |l JCL |c JCL-Sci |i 6438366 | ||
| 927 | |t Library of Congress classification |a RC374.C48 A58 2002 |l JCL |c JCL-Sci |e MARO |e CRERAR |b 61105366 |i 7350441 | ||
